Thymidine, 5'-amino-5'-deoxy- | 25152-20-9

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 2 '，5'-二脱氧核苷
• 英文名称: Thymidine, 5'-amino-5'-deoxy-
• 英文别名: 1-[5-(aminomethyl)-4-hydroxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
• CAS: 25152-20-9
• 化学式: C₁₀H₁₅N₃O₄
• 分子量: 241.24
• InChiKey: PYWLBQPICCQJFF-UHFFFAOYSA-N

物化性质

• 熔点：
  171 - 173°C
• 密度：
  1.394±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  105
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• [EN] TARGETING THYMIDINE KINASE PHOTOSENSITIZER AND PHARMACEUTICAL COMPOSITION AND USE FOR CANCER TREATMENT THEREOF<br/>[FR] PHOTOSENSIBILISANT CIBLANT UNE THYMIDINE KINASE ET COMPOSITION PHARMACEUTIQUE ET UTILISATION POUR LE TRAITEMENT DU CANCER ASSOCIÉ
  申请人：ZHEJIANG HISUN PHARM CO LTD

  公开号：WO2014056270A1

  公开（公告）日：2014-04-17

  本发明涉及制药领域，公开了一种靶向胸苷激酶光敏剂及其药物组合物与治疗癌症的用途。本发明所述的靶向胸苷激酶光敏剂增强了光敏剂对肿瘤细胞的选择性、具有更好的耐受性能够在24小时达到最高血药浓度。本发明所述的靶向胸苷激酶光敏剂具有更大共轭系统吸收波长更长有利于治疗深度肿瘤，该波长区域不需要耗费光输出设备很多能量，甚至使用LED即可，使PDT更具实用性和经济性。本发明所述靶向胸苷激酶光敏剂不仅可诊断，还可通过荧光成像引导用于治疗前列腺癌。本发明所述药物组合物将化疗剂与靶向胸苷激酶光敏剂组合联用，进一步提高了PDT法的治疗效果，扩大了肿瘤应用范围，对转移性肿瘤也具有很好的疗效。
• TARGETING THYMIDINE KINASE PHOTOSENSITIZER AND PHARMACEUTICAL COMPOSITION AND USE FOR CANCER TREATMENT THEREOF
  申请人：ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.

  公开号：US20160151494A1

  公开（公告）日：2016-06-02

  A targeting thymidine kinase photosensitizer and pharmaceutical composition and use for cancer treatment thereof is provided, which improves the selectivity of photosensitizers to tumor cells, has better tolerance, can reach maximum blood concentration in 24 hours, has a bigger conjugated system, a longer absorption wavelength and an advantage in treating depth tumors; the wavelength area does not need to consume much energy of a light-output device and even LEDs can be used, which render PDT more practical and economical. The targeting thymidine kinase photosensitizer can be used for diagnosis and for treating prostatic carcinoma via the guidance of fluorescence imaging. The pharmaceutical composition uses a combination of a chemotherapeutic agent and the targeting thymidine kinase photosensitizer, which further improves the therapeutic effect of the PDT method, expands the application range for tumors and has good effects on metastatic tumors as well.
• US9872903B2
  申请人：——

  公开号：US9872903B2

  公开（公告）日：2018-01-23